A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2009
12/10/2009	US20090306119 Non-Codeine Opioid Analgesic Process And Formulations
12/10/2009	US20090306115 Phenyl ethyne compounds
12/10/2009	US20090306110 N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
12/10/2009	US20090306102 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
12/10/2009	US20090306100 Methods of treating schizophrenia
12/10/2009	US20090306096 Novel Isoxazoles and Methods of Use Thereof
12/10/2009	US20090306092 Method for treating cognitive deficits
12/10/2009	US20090306088 Substituted heteroaryl pyridopyrimidone derivatives
12/10/2009	US20090306087 Compounds and Methods for Kinase Modulation, and Indications Therefor
12/10/2009	US20090306079 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands
12/10/2009	US20090306076 Morpholine Carboxamide Prokineticin Receptor Antagonists
12/10/2009	US20090306069 Azolidinone-vinyl fused-benzene derivatives
12/10/2009	US20090306051 Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
12/10/2009	US20090306050 Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
12/10/2009	US20090306047 Heterocyclic aspartyl protease inhibitors
12/10/2009	US20090306040 Mono and Combination Therapy of M1/M4 Agonist (Sabcomeline) for Treatment of Negative Symptoms of Schizophrenia
12/10/2009	US20090306015 Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
12/10/2009	US20090306001 Novel amphiphilic derivatives of alpha-c-phenyl-n-tert-butylnitrone
12/10/2009	US20090305991 33 Human Secreted Proteins
12/10/2009	US20090305989 Composition and method for potentiating drugs
12/10/2009	US20090305974 Therapeutic indications of colony stimulating factors
12/10/2009	US20090305951 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells
12/10/2009	US20090305365 Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof
12/10/2009	US20090305289 Screening method to identify protective substances for the treatment of neurodegenerative and/or ischaemic diseases
12/10/2009	US20090304830 Composition Comprising Bamboo Extract for Androgen Agonist
12/10/2009	US20090304819 Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance
12/10/2009	US20090304794 Controlled release formulations of pramipexole
12/10/2009	US20090304792 Granule and orally disintegrating tablet comprising oxycodone
12/10/2009	US20090304786 Stable Dosage Forms of an Antidepressant
12/10/2009	US20090304712 Neuronal Cell Death Inhibitor and Screening Method
12/10/2009	US20090304676 Compositions and methods for enhancing cognitive function
12/10/2009	US20090304661 Method And Composition For Proctecting Neuronal Tissue From Damage Induced By Elevated Glutamate Levels
12/10/2009	US20090304647 Production of Neural Stem Cells from Bone Marrow Tissue and Use Thereof
12/10/2009	US20090304596 Methods for Predicting Psychotropic Drugs Which Elicit Weight Gain
12/10/2009	DE10222561B4 Protektive Lösung zur Verhinderung von Ischämieschäden Protective solution for preventing ischemic damage
12/10/2009	DE102008027331A1 Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase The use of indole-3-carboxylic acid esters to inhibit the microsomal prostaglandin E2 synthase
12/10/2009	CA2727015A1 Treatment of pain with gap junction modulation compounds
12/10/2009	CA2726925A1 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
12/10/2009	CA2726878A1 Novel treatments
12/10/2009	CA2726874A1 Novel treatments
12/10/2009	CA2726833A1 Pharmaceutical compositions for treatment of parkinson's disease
12/10/2009	CA2726755A1 Selenophene and selenazole carboxylic acid derivatives
12/10/2009	CA2726644A1 Pharmaceutical combination
12/10/2009	CA2726285A1 Anxiolytic composition containing alphas1-casein-derived peptides
12/10/2009	CA2725740A1 3-substituted propanamine compounds
12/10/2009	CA2725538A1 Indane derivatives as ampa receptor modulators
12/10/2009	CA2725470A1 Sofinicline (abt-894 ) for attention-deficit/hyperactivity disorder
12/10/2009	CA2725356A1 Treatment for neurological and mental disorders
12/10/2009	CA2724199A1 Promoting axon regeneration in the adult cns through control of protein translation
12/10/2009	CA2723918A1 Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
12/10/2009	CA2723871A1 Process for the synthesis of .gamma. -amino acids
12/09/2009	EP2131198A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
12/09/2009	EP2130920A2 Beta-like glycoprotein hormone polypeptide and heterodimer
12/09/2009	EP2130829A1 Novel hydroxyindole derivative
12/09/2009	EP2130828A1 Sulfonamide derivative
12/09/2009	EP2130539A1 Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
12/09/2009	EP2130538A1 Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease
12/09/2009	EP2130533A1 Ataractic agent and functional food
12/09/2009	EP2129687A2 Novel glp-1 fusion peptides, their production and use
12/09/2009	EP2129673A1 Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
12/09/2009	EP2129672A1 Azaadamantane ester and carbamate derivatives and methods of use thereof
12/09/2009	EP2129670A2 Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
12/09/2009	EP2129655A1 Prolinamide derivatives as modulators of voltage-gated sodium channels
12/09/2009	EP2129383A1 Treatment of anxiety disorders with minocycline
12/09/2009	EP2129379A1 Imidazoquinolines as dual lipid kinase and mtor inhibitors
12/09/2009	EP2129377A1 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
12/09/2009	EP2129369A1 Treatment of adhd
12/09/2009	EP1745040B1 Azabicyclo(3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
12/09/2009	EP1732648B1 Treatment of diseases
12/09/2009	EP1648886B1 Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments
12/09/2009	EP1575578B1 Methods of treating injuries of the nervous system associated with hemorrhage
12/09/2009	EP1554256B1 Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
12/09/2009	EP1519939B1 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
12/09/2009	EP1458754B1 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/09/2009	EP1409450B1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
12/09/2009	EP1252144B1 Substituted glutarimides and use thereof il-12 production inhibitors
12/09/2009	CN101600700A Novel 2-aminooxazolines as TAAR1 ligands for CNS disorders
12/09/2009	CN101600698A Quinazolinone and isoquinolinone acetamide derivatives
12/09/2009	CN101600475A Small compounds that correct protein misfolding and uses thereof
12/09/2009	CN101600474A 1,3-dihydroimidazoles for treating cardiovascular disorders
12/09/2009	CN101600450A Treatment of demyelinating disorders
12/09/2009	CN101600438A Therapeutic agent for pain disease
12/09/2009	CN101600436A Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
12/09/2009	CN101600435A Agent for treatment of multiple sclerosis
12/09/2009	CN101600434A Stroke recovery
12/09/2009	CN101600433A Agent for prophylaxis or treatment of substance abuse and dependence
12/09/2009	CN101597337A Conjugate of hydroxyalkyl starch and an active agent
12/09/2009	CN101597294A 3-aminoalkaneacylamino-rutaecarpine and 3-aminoalkaneacylamino-7,8-dehydrorutaecarpine derivative
12/09/2009	CN101597262A Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/09/2009	CN101597260A Novel muscarinic receptor antagonist and application thereof
12/09/2009	CN101597212A Kirenol derivative and application thereof in preparation of proinflammatory cytokine inhibitor
12/09/2009	CN101596300A Traditional Chinese medicine sharpening-mind and inducing-consciousness microemulsion nasal cavity spraying agent and preparation method thereof
12/09/2009	CN101596261A Medicament for treating hydrocephalus and preparation method thereof
12/09/2009	CN101596260A Chinese patent medicine for treating epilepsy and postpartum epilepsy and preparation method thereof
12/09/2009	CN101596248A Application of gardenia extract in preparation of medicine for preventing and/or curing depressive anxiety
12/09/2009	CN101596233A Medicine composition used for preventing birth defects and improving memories
12/09/2009	CN101596232A Application of purified motherwort extract in preparing nerve protection medicine for treating cerebral injury
12/09/2009	CN101596222A Refined ginkgo biloba extract, powder and preparation method thereof
12/09/2009	CN101596216A Microbiological preparation for preventing or treating diabetes and related symptoms
12/09/2009	CN101596200A Preparation of compound of cycloartenyl ferulate and purification process thereof

1 ... 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 ... 1833